Clinical trial NCT05735301: Patient Selection Using MR With Non-Perfusion Imaging for Endovascular Treatment Within 6 to 24 Hours
Official title: Patient Selection Based on Penumbra-core Mismatch Using MR With Non-Perfusion Imaging for Endovascular Treatment Within 6 to 24 Hours: Rationale and Trial Design
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Endovascular Thrombectomy
Keywords: select patients
endovascular thrombectomy
magnetic resonance imaging
CT/MR perfusion
FVH-DWI mismatch
Lead sponsor: Tianjin Huanhu Hospital
Sponsor class: OTHER
First posted: 2023-02-21
Enrollment: 352
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: In this study, Patients will be screened, and image modality seletion be randomizied by a dedicated Clinical coordinator who is a non-treatment and non-follow-up participant. The randomization procedure will be computer- and web-based. Randomization is allowed when the occlusion has been established by MRA or CTA. All eligible subjects will be assigned to one of the following two treatment arms in the ratio of 1:1 after randomization:

1. None-Perfusion group.
2. Perfusion group.
Primary purpose: SCREENING

Brief summary: We will conduct a multicenter, prospective, randomized, open-label, blinded endpoint trial with a non-inferiority design in patients who present 6 to 24 hours after symptom onset with LVO. Patients who meet eligibility criteria will be randomly assigned to the Non-perfusion or Perfusion group with a 1:1 ratio. In the Non-perfusion group, patients with penumbra-core mismatch (defined as the FLAIR Vascular Hyperintensity (FVH) extending beyond the boundary of the DWI cortical lesions) will receive EVT. In the Perfusion group, patients with perfusion mismatch (defined as regional cerebral blood flow (\<30%) \< 70 ml with mismatch ratio ≥ 1.8 and mismatch volume ≥ 15 ml) will receive EVT. Patients in both groups will receive guideline-based medical treatment. If patients in both groups do not meet the criteria for EVT, only guideline-based medical treatment will be administered.

Detailed description: The theory of mismatch between ischemic core and penumbra has long been regarded as the triage criterion for stroke patients undergoing urgent endovascular treatment (EVT). In 1977, Astrup and colleagues first proposed the concept of ischemic penumbra through animal experiments. In 1981, Astrup defined ischemic penumbra as brain tissue surrounding the infarct core, with blood flow levels lower than those required to maintain normal brain function but higher than those causing structural changes in brain morphology . During cerebral ischemia, brain tissue exhibits a concentric distribution of varying degrees of ischemia. Tissue in the ischemic core has blood flow below 10 ml/100 g per minute and is considered irreversibly damaged. In contrast, tissue in the penumbra has blood flow between 10 and 17 ml/100 g per minute, indicating a risk of progressing to the infarct core . Patients with a high volume of penumbral tissue and a small infarct core, termed "mismatch," are deemed to derive the greatest benefit from EVT and are least likely to incur reperfusion injury risk. This principle has been consistently applied in clinical practice for stroke reperfusion, particularly in patients with late time windows, where reperfusion therapy is traditionally associated with potentially higher risks . Based on this principle, researchers utilize complex quantitative perfusion or infarct core calculation programs, often supported by artificial intelligence technology, to obtain high-quality clinical evidence. This strategy has proven successful. The efficacy and safety of EVT in patients with acute ischemic stroke (AIS) due to anterior circulation LVO is well established in multiple RCTs in the late treatment time windows (6 to 24 hours). EVT has significantly improved the prognosis of patients with LVO stroke compared to medical therapy .

DEFUSE 3 (Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3) and DAWN (DWI or CTP Assessment With Clinical Mismatch in the Triage of Wake-Up and Late Presenting Strokes Undergoing Neurointervention With Trevo) enrolled patients showing evidence of salvageable brain tissue, determined by the presence of significant mismatch. This mismatch describes a state where the volume of viable brain tissue at risk of infarction due to ongoing vessel occlusion greatly exceeds the volume of already infarcted tissue. Mismatch evaluation used computer-generated volumetric imaging criteria, either independently (DEFUSE 3) or with clinical-core infarction criteria (DAWN) . The AURORA trial conducted a meta-analysis of data from six late-onset trials, including DAWN, DEFUSE 3, ESCAPE, REVASCAT, POSITIVE, and RESILIENT, assessing common odds ratios, favorable prognosis rates, mortality rates, and other indicators. These findings strengthen the evidence supporting the benefits of EVT for patients showing evidence of reversible cerebral ischemia within the 6-24 hour time window and are relevant to clinical practice . Detection of core infarction and penumbral mismatch is considered an effective patient screening method, capable of identifying those most likely to benefit and excluding those most likely to suffer from reperfusion injury. However, the use of urgent CTP or PWI in the emergency department is often limited in many centers worldwide . The reasons include insufficient access to appropriate technological resources, manpower requirements, and software for analyzing perfusion imaging may not be readily available. Additionally, the strict inclusion criteria based on perfusion parameters in clinical trials hinder patient selection for real-world clinical practice, leading to some patients missing the opportunity for EVT. Therefore, additional clinical and imaging criteria facilitating the identification of eligible patients would be beneficial .

In a prospective study, the presence of FVH (defined as focal, tubular, or serpentine hyperintensity in the lateral fissure, sulcus, or near the surface of the brain on the 2D FLAIR sequence) was associated with acute stroke . The exact pathophysiological mechanism of FVH remains unclear; however, its emergence suggests slow blood flow, impaired antegrade blood flow, and retrograde blood flow near the ischemic lesion . Recent research suggests that the FVH sign could serve as a significant and convenient imaging marker indicative of inadequate perfusion in patients with cerebral infarction associated with LVO. Additionally, FVH has been suggested to indirectly indicate the presence of LVO or vascular stenosis, with insufficient collateral circulation and a perfusion abnormality. The discrepancy between DWI volume and the FVH sign (FVH-DWI mismatch) in acute stroke patients could serve as a valuable penumbra-core based triage tool without the need for perfusion imaging to predict functional outcomes after stroke.

In this study, we used a randomized controlled approach to assess the risk and prognosis of EVT by identifying the presence of an ischemic penumbra using the FVH-DWI mismatch. Our aim was to establish a simple evaluation method based on the indirect assessment of penumbra-core triage without perfusion imaging on MRI to screen patients who underwent thrombolysis within 6 to 24 hours from symptom onset. We hypothesized that triage using MRI with non-perfusion imaging would be non-inferior to using perfusion imaging in demonstrating 90-day functional independence.

Eligibility criteria: Inclusion Criteria:

* Age of 18 years or older；
* Anterior circulation LVO (internal carotid artery, or middle cerebral arteries (MCA)M1, M2 proximal segment) confirmed by computed tomographic angiography (CTA)/magnetic resonance angiography (MRA)；
* NIHSS score ≥6 at the time of randomization；
* ASPECTS score ≥ 6 on NCCT；
* Time from stroke onset to randomization within 6-24 hours；
* Pre-stroke mRS score 0-2；
* Completed MRI and perfusion imaging or enable to complete MRI and/or perfusion imaging；
* Signed informed consent

Exclusion Criteria:

* Pregnancy, or those potential with positive urine or serum beta Human Chorionic Gonadotrop in test；
* A history of severe allergy to contrast media；
* Uncontrolled hypertension (SBP \>185mmHg; DBP\>110mmHg)；
* Hereditary or acquired bleeding tendency, coagulation factor deficiency, recent anticoagulant medication (A platelet count of less than 100 x 109 /L；INR\>3 or PPT more than 3 times normal)；
* Active hemorrhage or preexisting tendency to hemorrhage；
* Presence of signs of cardiac, hepatic or renal failure；
* Baseline blood glucose\<50mg/dL (2.78mmol) or \>400mg/dL (22.20mmol)；
* Participation in other interventional randomized clinical trials that may confound the outcome assessment of the trial；
* Life expectancy \< 1 year；
* Patients who are unable to complete the 90-day follow-up；
* A stroke attack with epilepsy that prevents an accurate NIHSS score from being obtained；
* Other circumstances that the investigator considers inappropriate for participation in the trial(such as violation of guidelines or institutional processing principles during the screening process).

Primary outcomes:
measure: Functionally independent outcome in all enrolled patients
timeFrame: 90 days
Secondary outcomes:
measure: Modified Rankin scale scores at 90 days
timeFrame: 90 days
measure: Successful reperfusion after endovascular treatment
timeFrame: immediately the surgeon thought the thrombectomy completed and performed a second cerebral angiography
measure: Recanalization rate
timeFrame: 72 hours
measure: Final infarct volume
timeFrame: 72hours
measure: NIHSS score
timeFrame: 24 hours、72hour sand 7 days postoperatively
measure: Quality of life assessment at 90 days
timeFrame: 90 days
measure: mortality
timeFrame: 90 days
measure: symptomatic intracranial hemorrhage
timeFrame: 48 hours
measure: FVH-ASPECT score
timeFrame: 24 hours、72hour sand 7 days postoperatively
Other outcomes:
Locations:
city: Tianjin
country: China
facility: TianJinHH
state: Tianjin
Study officials:
affiliation: Tianjin Huanhu Hospital
name: Ming Wei, doctorate
role: PRINCIPAL_INVESTIGATOR
References: